TCT 2023: Six-Month Clinical Data from DESyne® BDS Plus Randomized Controlled Trial (RCT) Support Safety and Effectiveness of World’s First Site-Specific Antithrombotic Drug Therapy
Elixir shares 8 Presentations highlighting company's transformational technology innovations at TCT 2023.
Randomized Clinical Dataset Featuring World’s First Triple Drug-Eluting Coronary Implant Eluting Two Anticoagulants and Sirolimus At TCT 2023
The DESyne BDS Plus RCT includes 202 patients across 14 sites in Europe, New Zealand and Brazil.
Job Post Template
Major Duties and Responsibilities Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim venia
Elixir Medical Completes Enrollment of INFINITY-SWEDEHEART Clinical Trial
The trial, which includes 2,400 patients from 20 sites across Sweden, compares DynamX Bioadaptor to Resolute Onyx.
DynamX Bioadaptor Restores Rotational Motion and Vessel Stress Reduction in New Study
A study in the latest issue of Cardiovascular Revascularization Medicines hows that the DynamX™ Coronary Bioadaptor System, when uncaged, enabled rotational motion similar to nat
Elixir Medical Expands Bioadaptor Randomized Controlled Trial of DynamX Coronary Bioadaptor System
MILPITAS, Calif. – April 22, 2021 – Elixir Medical, a developer of innovative, drug-eluting cardiovascular devices, today announced that the BIOADAPTOR randomized controlled
Elixir Medical Announces Commencement Of Infinity-Swedeheart Randomized Controlled Trial of DynamX Coronary Bioadaptor System
2,400-Patient Trial Utilizes Globally-Respected SWEDEHEART Registry Database in Randomized Study of First Metallic Device Treating Coronary Artery Disease That Adapts to Vessel Phy